Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study, Role as a Prognostic Factor and an Immune-Suppressive Biomarker

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Vilariño, Noelia|||0000-0001-5115-6628
  • Alameda, Francesc|||0000-0002-7302-6901
  • Mojal, Sergi|||0000-0003-0523-3869
  • Arumí-Uria, Montserrat|||0000-0003-0341-9686
  • Carrato, Cristina|||0000-0002-1953-8287
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Ribalta Farres, Teresa|||0000-0003-2692-0051
  • Vidal, Noemí|||0000-0002-2852-6667
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Menéndez, Sílvia|||0000-0002-9116-8743
  • Del Barco Berrón, Sonia|||0000-0002-4951-6871
  • Gallego, Oscar S.
  • Pineda, Estela|||0000-0003-2128-747X
  • Lopez Martos, Raquel|||0009-0003-4328-9094
  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Mesia, Carlos
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Balañá, Carmen|||0000-0003-0771-0390
  • Martinez Garcia, Maria|||0000-0001-5891-3935
  • Navarro, Pilar|||0000-0003-4314-4584
Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

  • Cabrero-de las Heras, Sara|||0000-0002-9364-5371
  • Hernández-Yagüe, Xavier|||0000-0002-3742-1218
  • González Valencia, Andrea|||0009-0005-4236-0199
  • Losa, Ferran|||0000-0003-0111-8708
  • Soler, Gemma
  • Bugés, Cristina|||0000-0003-2013-1510
  • Baraibar, Iosune|||0000-0002-3500-9641
  • Esteve, Anna|||0000-0002-1962-971X
  • Pardo-Cea, Miguel Ángel|||0000-0003-4823-6613
  • Ree, Anne Hansen
  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Nieva, Maria
  • Musulén, Eva|||0000-0002-9667-6464
  • Meltzer, Sebastian
  • Lobato, Tania
  • Vendrell-Ayats, Carla|||0009-0000-2740-0918
  • Queralt, C|||0000-0001-9875-0173
  • Navarro, Pilar|||0000-0003-4314-4584
  • Montagut Viladot, Clara|||0000-0003-1438-2903
  • Grau-Leal, Ferran|||0000-0003-3072-2250
  • Camacho Martín, David
  • Legido, Raquel
  • Mulet-Margalef, Nuria|||0000-0002-2385-6448
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-line oxaliplatin-based treatment to pinpoint predictive and prognostic markers. Serum samples were collected before treatment, at response evaluation (EVAR), and at disease progression or last follow-up. Chemokines were assessed in all samples using a Luminex® custom panel. CXCL13 levels increased at EVAR in responders, while in non-responders it decreased. Increasing levels of CXCL13 at EVAR, independently correlated with improved progression-free survival (PFS) and overall survival (OS). Nanostring® analysis in primary tumor samples showed CXCL13 gene expression's positive correlation not only with gene profiles related to an immunogenic tumor microenvironment, increased B cells and T cells (mainly CD8+) but also with extended OS. In silico analysis using RNAseq data from liver metastases treated or not with neoadjuvant oxaliplatin-based combinations, and deconvolution analysis using the MCP-counter algorithm, confirmed CXCL13 gene expression's association with increased immune infiltration, improved OS, and Tertiary Lymphoid Structures (TLSs) gene signatures, especially in neoadjuvant-treated patients. CXCL13 analysis in serum from 36 oxaliplatin-treated patients from the METIMMOX study control arm, reported similar findings. In conclusion, the increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in mCRC patients undergoing oxaliplatin-based treatment.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo-Campos, M. A.
  • Lutfi, Nuria
  • Bonnin, S.
  • Martínez, C.
  • Velasco-Hernández, Talia
  • García-Hernández, V.
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, R.
  • Colomo, L.
  • Roué, Gaël
  • Guilbaud, G.
  • Dantzer, Françoise
  • Navarro Medrano, Pilar
  • Murga, Matilde
  • Fernández-Capetillo, Óscar
  • Bigas, A.
  • Menéndez, Pablo
  • Sale; J. E.
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the E¿-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic E¿-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors., The J.Y. laboratory is funded by the Spanish Ministerio de Economía, Industria y Competitividad (grant SAF2017-83565-R), Spanish Ministerio de Ciencia e Innovación (grant PID2020-112526RB-I00), and Fundación Científica de la Asociación Española Contra el Cáncer (grant PROYEI6018YÉLA). Work in the J.E.S. laboratory is supported by a core grant to the Laboratory of Molecular Biology from the Medical Research Council (U105178808). The F.D. laboratory is supported by a Laboratory of Excellence grant (ANR-10-LABX-0034_Medalis) to Strasbourg University, Centre National de la Recherche Scientifique. The P.N. laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness/Instituto de Salud Carlos III–Fondo Europeo de Desarrollo Regional (FEDER; PI17/00199 and PI20/00625) and the Generalitat de Catalunya (2017-SGR-225). The P.M. laboratory acknowledges support from Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the Spanish Ministry of Economy and Competitiveness (grant SAF-2019-108160-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (grant LCF/PR/HR19/52160011), and the German Josep Carreras Leukamie Stiftung. Work at the G.R. and P.M. laboratories are cofinanced by the European Regional Development Fund through the Interreg V-A Spain-France-Andorra Program (project PROTEOblood; grant EFA360/19). The O.F.-C. laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTI2018-102204-B-I00; cofinanced with European FEDER funds) and the European Research Council (ERC-617840). T.V.-H. was supported by a Marie Sklodowska Curie fellowship (GA792923). The A.B. laboratory is supported by the Spanish Ministry of Economy and Competitiveness (grant PID2019-104695RB-I00)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

  • Cabrero-de Las Heras, Sara
  • Hernández-Yagüe, Xavier
  • González, Andrea
  • Losa, Ferran
  • Soler, Gemma
  • Bugés, Cristina
  • Baraibar, Iosune
  • Esteve, Anna
  • Pardo-Cea, Miguel Ángel
  • Ree, Anne Hansen
  • Martínez-Bosch, Neus
  • Nieva, Maria
  • Musulén, Eva
  • Meltzer, Sebastian
  • Lobato, Tania
  • Vendrell-Ayats, Carla
  • Queralt, Cristina
  • Navarro Medrano, Pilar
  • Montagut, Clara
  • Grau-Leal, Ferran
  • Camacho, David
  • Legido, Raquel
  • Mulet-Margalef, Núria
  • Martínez-Balibrea, Eva
Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-line oxaliplatin-based treatment to pinpoint predictive and prognostic markers. Serum samples were collected before treatment, at response evaluation (EVAR), and at disease progression or last follow-up. Chemokines were assessed in all samples using a Luminex® custom panel. CXCL13 levels increased at EVAR in responders, while in non-responders it decreased. Increasing levels of CXCL13 at EVAR, independently correlated with improved progression-free survival (PFS) and overall survival (OS). Nanostring® analysis in primary tumor samples showed CXCL13 gene expression's positive correlation not only with gene profiles related to an immunogenic tumor microenvironment, increased B cells and T cells (mainly CD8+) but also with extended OS. In silico analysis using RNAseq data from liver metastases treated or not with neoadjuvant oxaliplatin-based combinations, and deconvolution analysis using the MCP-counter algorithm, confirmed CXCL13 gene expression's association with increased immune infiltration, improved OS, and Tertiary Lymphoid Structures (TLSs) gene signatures, especially in neoadjuvant-treated patients. CXCL13 analysis in serum from 36 oxaliplatin-treated patients from the METIMMOX study control arm, reported similar findings. In conclusion, the increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in mCRC patients undergoing oxaliplatin-based treatment., This work has been funded by the ISCIII grant from the Spanish Government, project number PI16/01800 and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project number 2017-SGR-723, both of them awarded to Dr. Martinez-Balibrea and it is based in part upon work from COST Action CA21135, supported by COST (European Cooperation in Science and Technology). Dr. Pilar Navarro was supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/ ISCIII-FEDER (PI20/00625 and PI23/00591). Ferran Grau-Leal is supported by an AGAUR-FI grant ( 2023 FI-3 00065 ) from the predoctoral program Joan Oró of the Secretaria d′Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya and the European Social Funds Plus. Carla Vendrell-Ayats holds an INVESTIGO program contract from the Generalitat de Catalunya, funded by the EU, Next Generation European Funds. Miguel Angel Pardo-Cea was supported by a PERIS PFI-Salut SLT017–20–000076 grant from the Generalitat de Catalunya; METIMMOX study was funded by the Norwegian Cancer Society, including its Umbrella Foundation for Cancer Research, grants 182496 and 215613 and the South-Eastern Norway Regional Health Authority grants 2018054 ., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hallmarks of pancreatic cancer: spotlight on TAM receptors

  • Vázquez-Bellón, Núria
  • Martínez-Bosch, Neus
  • García de Frutos, Pablo
  • Navarro Medrano, Pilar
Pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need., This work was supported by grants from the Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) (PI20/00625 and PI23/00591) to PN, 8th “Beca Carmen Delgado” to PN and PGF and grants from the MICIU (PID2021-123564OB-100) to PGF. The funders did not have any role in paper design, data collection, data analysis, interpretation, or writing of the paper. NV-B is supported by a FPU (“Formación de Profesorado Universitario”) predoctoral contract from the MICIU (FPU21/0928). The authors did not receive remuneration for their participation. We thank TPM Science for English proofreading and manuscript editing., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Quantitative characterization of the 3D self-organization of PDAC tumor spheroids reveals cell type and matrix dependence through advanced microscopy analysis

  • Hernández-Hatibi, Soraya
  • Borau, Carlos
  • Martínez-Bosch, Neus
  • Navarro, Pilar
  • García-Aznar, José Manuel
  • Guerrero, Pedro Enrique
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an abundant tumor-associated stroma composed from pancreatic stellate cells, which play a critical role in tumor progression. Developing accurate in vitro models requires understanding the complex interactions between tumor cells and their microenvironment. In this study, we present a quantitative imaging-based characterization of the three dimensional (3D) self-organization of PDAC tumour spheroids using a microfluidic platform that mimics key aspects of the tumor microenvironment. Our model incorporates collagen type I hydrogels to recreate the extracellular matrix, activated human pancreatic stellate cells (HPSCs), and various tumor cell types. Advanced imaging techniques, including Lattice Lightsheet Microscopy, allowed us to analyze the 3D growth and spatial organization of the spheroids, revealing intricate biomechanical interactions. Our results indicate that alterations in matrix properties—such as stiffness, pore size, and hydraulic permeability—due to variations in collagen concentration significantly influence the growth patterns and organization of PDAC spheroids, depending on tumor subtype and epithelial–mesenchymal phenotype. Higher collagen concentrations promoted larger spheroids in epithelial-like cell lines, while mesenchymal-type cells required increased collagen for self-organization into smaller spheroids. Furthermore, coculture with HPSCs affected spheroid formation distinctly based on each PDAC cell line's genetic and phenotypic traits. HPSCs had opposing effects on epithelial-like cell lines: one cell line exhibited enhanced spheroid growth, while another showed inhibited formation, whereas mesenchymal-like spheroids showed minimal impact. These results provide insights into tumor–stroma interactions, emphasizing the importance of the cell-specific and matrix-dependent factors for advancing our understanding of PDAC progression and informing future therapeutic strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Cristóbal, Helena
  • Iglesias, Mar|||0000-0002-2274-4671
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Barranco, Luis E
  • Visa, Laura|||0000-0002-3409-8857
  • Calafato, Domenico|||0000-0002-9636-9819
  • Jiménez-Parrado, Silvia
  • Earl, Julie
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Manero-Rupérez, Noemí
  • Moreno Merino, Mireia|||0000-0001-9575-5112
  • Morales, Albert|||0000-0001-8702-2269
  • Guerra, Carmen
  • Navarro, Pilar|||0000-0003-4314-4584
  • García de Frutos, Pablo|||0000-0003-1547-1190
Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. Here we explore the use of sAXL as a biomarker for PDAC. AXL was analysed by immunohistochemistry in human pancreatic tissue samples. RNA expression analysis was performed using TCGA/GTEx databases. The plasma concentrations of sAXL, its ligand GAS6, and CA19-9 were studied in two independent cohorts, the HMar cohort (n = 59) and the HClinic cohort (n = 142), including healthy controls, chronic pancreatitis (CP) or PDAC patients, and in a familial PDAC cohort (n = 68). AXL expression and sAXL release were studied in PDAC cell lines and murine models. AXL is increased in PDAC and precursor lesions as compared to CP or controls. sAXL determined in plasma from two independent cohorts was significantly increased in the PDAC group as compared to healthy controls or CP patients. Patients with high levels of AXL have a lower overall survival. ROC analysis of the plasma levels of sAXL, GAS6, or CA19-9 in our cohorts revealed that sAXL outperformed CA19-9 for discriminating between CP and PDAC. Using both sAXL and CA19-9 increased the diagnostic value. These results were validated in murine models, showing increased sAXL specifically in animals developing PDAC but not those with precursor lesions or acinar tumours. sAXL appears as a biomarker for early detection of PDAC and PDAC-CP discrimination that could accelerate treatment and improve its dismal prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo Campos, Miguel A.|||0000-0002-0650-8660
  • Lutfi, Nura
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Martínez Cáceres, Carlos|||0000-0003-3307-1326
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • García-Hernández, Violeta|||0000-0003-2328-4360
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, Ramón|||0000-0002-8758-121X
  • Colomo, Luis|||0000-0001-5236-5085
  • Roué, Gaël|||0000-0003-0245-2257
  • Guilbaud, Guillaume|||0000-0002-4345-6855
  • Dantzer, Françoise
  • Navarro, Pilar|||0000-0003-4314-4584
  • Murga, Matilde|||0000-0002-9766-4481
  • Fernández Capetillo, Oscar|||0000-0002-2690-6885
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Sale, Julian E.
  • Yélamos, José|||0000-0003-1195-1496
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors.